Inteliquent Rating Increased to Outperform at Zacks (IQNT)

Share on StockTwits

Inteliquent (NASDAQ:IQNT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Tuesday, American Banking and Market News reports. The firm currently has a $15.20 price objective on the stock. Zacks‘s price objective would suggest a potential upside of 10.87% from the stock’s previous close.

Shares of Inteliquent (NASDAQ:IQNT) traded down 1.02% on Tuesday, hitting $13.57. 275,756 shares of the company’s stock traded hands. Inteliquent has a 52-week low of $2.93 and a 52-week high of $15.31. The stock has a 50-day moving average of $14.12 and a 200-day moving average of $12.27. The company has a market cap of $437.8 million and a P/E ratio of 8.05.

Inteliquent (NASDAQ:IQNT) last released its earnings data on Thursday, February 27th. The company reported $0.27 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.09. The company had revenue of $50.20 million for the quarter, compared to the consensus estimate of $50.11 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s quarterly revenue was down 13.0% on a year-over-year basis. Analysts expect that Inteliquent will post $0.90 EPS for the current fiscal year.

Inteliquent Inc, formerly Neutral Tandem, Inc, doing business as Inteliquent provides solutions for voice, data, and hosted services globally.

To view Zacks’ full report, visit Zacks’ official website.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Study: Probiotics Recipe Could Help Control Weight
Study: Probiotics Recipe Could Help Control Weight
Companies Paying For Posts on Social Networks
Companies Paying For Posts on Social Networks
Amazon Sees Wider Loss on Spending
Amazon Sees Wider Loss on Spending
Bristol-Myers Tops Forecast Thanks to New Drugs
Bristol-Myers Tops Forecast Thanks to New Drugs
Biogen Idec Sales and Profit Fly Past Projections
Biogen Idec Sales and Profit Fly Past Projections
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal


Leave a Reply

 
© 2006-2014 WKRB News.